Clinical Research
COSA Annual Scientific Meeting 2013
Days
Tuesday, 12th November
Wednesday, 13th November
Thursday, 14th November
Tracks
Basic and Translational Research
Clinical Research
Education
Epidemiology
Health Services
Supportive Care
GI Cancers
Geriatric Oncology
Service Provision (poster only)
Trials in Progress (poster only)
Search
Speakers
Posters - Clinical research
3:00PM - 4:00PM
Tuesday, 12th November
Hall H - exhibition
DENOSUMAB induced Hypocalcaemia in Advanced cancers at the Top End; Severity and Management
-
Alison Buete
Long-Term Survival in Patients with Metastatic Melanoma who Received Ipilimumab in Four Phase II Trials
-
Kevin Chin
Survival Analysis with 5 years of Follow-Up in a Phase III Study of Ipilimumab and Dacarbazine in Metastatic Melanoma
-
Kevin Chin
RCT of Colonic Stent Insertion vs. Surgical Decompression for Patients with Malignant Incurable Large Bowel Obstruction
-
Katie De-loyde
Monitoring clinical studies – improving quality
-
Belinda Fazekas
Evaluation of an Education Program to Facilitate Patient Adherence, Toxicity Monitoring and Promote Safety and Wellbeing in the Self Administration of Oral Chemotherapy in the Home Setting
-
Tina Griffiths
A Drug-Interaction Study of Effects of Calcium and Magnesium Infusions on Oxaliplatin Pharmacokinetics, Motor Nerve Hyperexcitability and Acute Neurotoxicity Symptoms in Colorectal Cancer Patients
-
Catherine H Han
Retrospective Review of Hypersensitivity Reactions to Paclitaxel with Oral Versus Intravenous Dexamethasone, Antihistamine and H2-Antagonist Premedication.
-
Michelle Hong
Granulocytic Sarcoma of the Bladder as the Sole Manifestation of Acute Myelogenous Leukemia: a case report and literature review
-
Abdel Nasser Hosein
Development of Guidelines to Inform the Content of Summarized Patient Information Forms (SPIFs) Regarding Cancer-Related, Clinical Trials
-
Chi-Yin Kao
Survival of Patients with Resected Cerebral Metastases from Gastrointestinal Cancers
-
David Lau
A Pilot Study of a Healthy Lifestyle Self-Management Intervention with Cancer Survivors
-
Sharon Lawn
Late Effects of Oxaliplatin-induced peripheral Neuropathy (LEON)
-
Jaein Lee
CHARM Utility study
-
Yeh Chen Lee
Monitoring and treatment of hypomagnesaemia in patients receiving cetuximab
-
Bill Loukas
Ipilimumab Retreatment Following Induction Therapy: The Expanded Access Program (EAP) Experience
-
Tracy Michener
A Prospective Study of Anti-Mullerian Hormone (AMH) As a Potential Predictor of Chemotherapy-Induced Menopause: Preliminary Results.
-
Jessica Miller
An introduction to ICCon - Inherited Cancer Connect Partnership
-
Gillian Mitchell
Physical Activity (PA) Participation for Women with Ovarian Cancer
-
David Mizrahi
Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes after Positive Sentinel Lymph Node Biopsy in Melanoma Patients: Westmead Melanoma Unit Experience and a Review of Literature
-
Vinayak Nagaraja
Metastatic central nervous system recurrence in breast cancer: Impact of tumour sub-type
-
Brent O'Carrigan
The Prostate Cancer Journey: Results of an Online Survey of Men and their Partners.
-
Kevin O'Shaughnessy
Impaired Sexual Function and Prostate Cancer; A Mixed Method Investigation into the Experiences of Men and their Partners
-
Kevin O'Shaughnessy
Audit of Patient Selection and Protocols for Prostate Cancer Active Surveillance in South Australia
-
Lovelace Osei-Tutu
Qualitative Results of the LEON study: Late Effects of Oxaliplatin-Induced Peripheral Neuropathy
-
Sunita Padman
Incidence of gastrointestinal toxicity with capecitabine monotherapy in metastatic breast and metastatic colorectal cancer patients
-
James Kuo
Barriers to Recruitment for a Post-Cancer Fatigue Intervention Study - The TOPS Trial.
-
Carolina Sandler
Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review
-
Jingli Song
Hypocalcaemia in patients with metastatic bone disease (MBD) receiving denosumab
-
Richard H De Boer
Meta-Analysis of Progression-Free Survival Impact of Biological Therapy in Relapsed Metastatic Colorectal Cancer
-
David Chan
Best of the Best Orals: Clinical research
4:00PM - 5:30PM
Tuesday, 12th November
Meeting room 5
Chairs: Alan Coates & Vanessa Blair
OPTiM: a randomised phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma
-
Robert HI Andtbacka
Prognostic Significance, Accuracy and Usefulness of Oncologists Estimates of Survival Time for Patients Starting First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (ANSCLC)
-
Belinda E Kiely
Treatment Outcomes of Rapid Desensitisation Protocols for Chemotherapeutic Agents and Monoclonal Antibodies following Hypersensitivity Reactions.
-
James C Kuo
Disease and Patient Characteristics related to Survival in a large population-based cohort of patients with Malignant Pleural Mesothelioma (MPM)
-
Anthony Linton
Somatic Mutations in Metastatic Melanoma in a large cohort of Australian patients
-
Megan Lyle
Prognostic Value of Early Objective Tumor Response (EOTR) to First Line Systemic Therapy in Metastatic Colorectal Cancer (Mcrc): Individual Patient Data (IPD) Meta-Analysis of Randomized Trials from the ARCAD Database
-
Dirkje W Sommeijer